Skip to main content
. 2017 May 3;206(2):811–828. doi: 10.1534/genetics.116.197590

Table 6. rad9Δ instabilities using different chemical growth media.

Genotype Unstable Chr. (×10−5) Allelic rec. (×10−5) Chr. loss (×10−4)
Median (Q1, Q3) Fold stabil. Median (Q1, Q3) Fold stabil. Median (Q1, Q3) Fold stabil.
rad9Δ 57 (40, 71) 1 6.0 (2.8, 8.2) 1 22 (16, 39) 1
Cycloheximide rad9Δ 0.04 μg/ml cyc. 78 (67, 99) 0.73 8.4 (4.6, 12) 0.71 47 (28, 57) 0.47
rad9Δ 0.06 μg/ml cyc. 86 (67, 97) 0.66 6.4 (3.1, 12) 0.94 36 (19, 53) 0.61
D-glucosamine rad9Δ 2% Dex, 0.2% D-gluc 62 (54, 90) 0.92 2.2 (1.1, 4.8) 2.7 6.9 (6.0, 8.2) 3.2*
rad9Δ 2% Dex, 0.7% D-gluc 72 (43, 130) 0.79 9.0 (8.1, 9.3) 0.67 11 (7.1, 16) 2.0
rad9Δ 2% Dex, 1.0% D-gluc 33 (23, 42) 1.7 1.1 (0.28, 4.3) 5.5* 30 (14, 51) 0.73
rad9Δ 2% Dex, 1.8% D-gluc 27 (19, 30) 2.1* 3.3 (2.2, 5.9) 1.8 14 (8.8, 19) 1.6
Myriocin rad9Δ 800 ng/ml myriocin 59 (52, 71) 0.97 7.0 (4.7, 10) 0.86 10 (8.7, 16) 2.2*
rad9Δ 1000 ng/ml myriocin 43 (36, 50) 1.3 2.2 (1.4, 3.0) 2.7* 5.8 (4.9, 8.1) 3.8*
NaCl rad9Δ 0.125 M NaCla 33 (27, 36) 1.7 2.5 (2.0, 7.5) 2.4 21 (12, 27) 1.00
rad9Δ 0.25 M NaCla 44 (34, 55) 1.3 13 (11, 17) 0.46* 92 (60, 105) 0.24
rad9Δ 0.5 M NaCla 47 (35, 54) 1.2 12 (10, 14) 0.50* 76 (67, 130) 0.30*
rad9Δ 1.0 M NaCla 120 (94, 180) 0.48* 9.0 (5.5, 23) 0.67 4900 (3900, 6300) 0.0045*
YEPG rad9Δ 2% glycerolb 29 (15, 31) 2.0 2.5 (1.4, 6.1) 2.4 710 (350, 810) 0.031*

Instability frequencies and genome fold stabilization of rad9Δ grown on media plates containing various concentrations of cycloheximide (protein synthesis inhibitor), D-glucosamine (glucose competitor), myriocin (sphingolipid inhibitor), NaCl (osmotic stress inducer), and YEPG (glycerol, respiration energy source) normalized to rad9Δ grown on YEPD media plates. Cells with a light gray background indicate genome fold stabilization increase; cells with a white background indicate decreased fold stabilization (<1.0 = increased instability) or no change in stabilization (=1.0). Statistically significant appears in boldface type. Kruskal–Wallis test, * P < 0.01.

a

Viability not tested.

b

Sample size: N = 5.